SofPort lenses win NTIOL status

Article

Bausch & Lomb has received new technology intraocular lens (NTIOL) status for the regular and violet-filtering models of its SofPort Advanced Optics intraocular lenses (IOLs).

Bausch & Lomb has received new technology intraocular lens (NTIOL) status for the regular and violet-filtering models of its SofPort Advanced Optics intraocular lenses (IOLs).

The Centers for Medicare and Medicaid Services (CMS) in the US has increased the current reimbursements for both lenses by $50. Only ASC-based surgeons are entitled to this additional reimbursement, however, this does represent a large portion of the cataract procedures performed in the US.

According to Bausch & Lomb, this new reimbursement will cover the entire cost of the IOLs, which means that patients will no longer have to pay for any additional costs.

Bausch & Lomb's SofPort lenses, which feature an aberration-free design, were able to demonstrate clinical benefit at least equal to the Tecnis IOL (Advanced Medical Optics), which established the NTIOL subset for aberration reduction.

The increased reimbursements will remain in effect until February 26, 2011.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.